<u>Claims</u>

1. A chimeric analog comprising (1) at least one moiety which binds to one or more somatostatin receptor(s) and (2) at least one moiety which binds to one or more dopamine receptor(s), or a pharmaceutically acceptable salt thereof.

2. The chimeric analog of claim 1, wherein said chimeric analog comprises formula (I),



wherein:

X is H, Cl, Br, I, F, -CN, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, or substituted $C_{2-10}$ alkynyl;

R1 is H, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkynyl, or -CN;

R2 and R3, each is, independently, H or absent, provided that when R2 and R3 are absent a double bond is present between the carbon atoms to which they are attached;

R4 is H, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, or substituted $C_{2-10}$ alkynyl;

Y is -O-, -C(O)- , -S-, -S-$(CH_2)_s$-C(O)-, -S(O)-, -S(O)$_2$-, -SC(O)-, -OC(O)-, -N(R5)-C(O)-, or -N(R6)-;

L is -$(CH_2)_p$-C(O)-, when Y is -S-, -S(O)-, -S(O)$_2$-, -O- or -N(R6)-; or L is -C(O)-$(CR7R8)_q$-C(O)-, when Y is -N(R6)-, -O-, or -S-; or L is (amino acid)$_t$, when Y is -C(O)-, SC(O)-, -OC(O)-, -S-$(CH_2)_s$-C(O)-, or -N(R5)-C(O)-;

W is $-CR9,R10-$

R5 and R6 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted alkylaryl;

R7, R8, R9, and R10 each is, independently, H, F, Cl, Br, I, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl; or R7 and R8 can, optionally, join together to form a ring system; or R9 and R10 can, optionally, join together to form a ring system;

i is 1-10, provided that when i is 1, then R1 is not H, $C_{1-4}$ alkyl, allyl, alkenyl or $-CN$, R4 is not H or $-CH_3$, R5, R6, R7 and R8 each is, independently, not H or $C_{1-5}$ alkyl, L is not $-(Doc)t-$, X is not H, Cl, Br, I, F, $-CN$, or $C_{1-5}$ alkyl, or R9 and R10 each is, independently, not H;

m is 0 or 1;

n is 0-10;

p is 1-10;

q is 1-5;

s is 1-10;

t is 1-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

3.    The chimeric analog of claim 1, wherein said chimeric analog comprises formula (II),



(II)

wherein:

X is H, Cl, Br, I, F, -CN, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, or substituted $C_{2-10}$ alkynyl;

R1 is H, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkynyl, or -CN;

R2 and R3, each is, independently, H or absent, provided that when R2 and R3 are absent a double bond is present between the carbon atoms to which they are attached;

R4 is H, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, or substituted $C_{2-10}$ alkynyl;

R5 is H, $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{1-10}$ alkyl, substituted $C_{1-10}$ heteroalkyl, substituted $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkynyl, or a group of the formula of $-(CH_2)_r N(R11,R12)$;

Y is -O-, -C(O)- , -S-, -SC(O)-, -OC(O)-, -N(R6)-C(O)-, -N(R7)-, or -N(R8)-$(CH_2)_s$-C(O)-;

L is -$(CH_2)_p$-C(O)-, when Y is -S-, -O- or -N(R7)-; or L is -C(O)-$(CR9R10)_q$-C(O)-, when Y is -N(R7)-, -O-, or -S-; or L is (amino acid)$_t$, when Y is -C(O)-, SC(O)-, -OC(O)-,  -N(R8)-$(CH_2)_s$-C(O)-, or -N(R6)-C(O)-;

89

W is $-CR9,R10-$;

R6, R7, and R8 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl, $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

R9, and R10 each is, independently, H, Cl, Br, I, F, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl; or R9 and R10 can, optionally, join together to form a ring system;

R11, and R12 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10, provided that when i is 1, then R1 is not H, $C_{1-4}$ alkyl, allyl, alkenyl or $-CN$, R4 is not H or $-CH_3$, R5 is not $C_{1-5}$ alkyl group or a group of the formula of $-(CH_2)_rN(CH_3)_v$, R6, R7, R8, R9 and R10 each is, independently, not H or $C_{1-5}$ alkyl, L is not $-(Doc)t-$, or X is not H, Cl, Br, I, F, $-CN$, or $C_{1-5}$ alkyl;

m is 0 or 1;

n is 2-10;

p is 1-10;

q is 1-5;

r is 1-8 ;

s is 1-10;

t is 1-10;

v is 2-4;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

4.    The chimeric analog of claim 1, wherein said chimeric analog comprises formula
      (III),

$$\left[ \begin{array}{c} R4-O \\ R5-O-\bigcirc-(W)_n-\underset{R2}{\overset{R1}{\underset{|}{\overset{|}{Q}}}}-X \end{array} -Z \right]_i$$

                                        (III)

wherein:

R2 is H, -N(R11)N(R12,R13), –N(R6R7), or -COOH;

R4 and R5 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$
heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$
alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, substituted
akylaryl or R8-C(O)-;

W is –CR9R10- or –(CH$_2$)$_q$-NH-(CH$_2$)$_r$-;

R1, R6, R7, R8, R11, R12 and R13 each is, independently, H, $C_{1-10}$ alkyl,
substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$
alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl,
alkylaryl, or substituted akylaryl;

R9 and R10 each is, independently, H, -OH, -CN, -NO$_2$, F, Cl, Br, I, $C_{1-10}$
alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl,
$C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl,
akylaryl, substituted alkylaryl, or aryl;

X is $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$
heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted
$C_{2-10}$ alkynyl, akylaryl, substituted alkylaryl, aryl, or acyl;

Q is C or N; provided that when Q is N, then R2 is absent;

i is 1-10;

n is 1-6;

q is 1-6;

r is 1-8;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

5.    The chimeric analog of claim 1, wherein said chimeric analog comprises formula (IV),



(IV)

wherein:

R1 and R2 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

R3, R4, R5, R6 and R7 each is, independently, H, -OH, -CN, -NO$_2$, F, Cl, Br, I, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

W is $-CR4R5-$;

Y is $-(CR6R7)_m-C(O)-$ or acyl;

m is 0-10;

n is 1-6;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

6.  The chimeric analog of claim 1, wherein said chimeric analog comprises formula (V),



(V)

wherein:

P is –N(R3R4) or H;

X is N or S;

W is –CR5R6–;

Y is –(CR7R8)$_m$-C(O)–;

R1, R3 and R4 each is, independently, H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

R2, R5, R6, R7 and R8 each is, independently, H, -OH, -CN, -NO$_2$, F, Cl, Br, I, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

n is 0-6;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

7.  The chimeric analog of claim 1, wherein said chimeric analog comprises formula (VI),

(VI)

wherein:

Y is –(CR2R3)$_m$-C(O)- or acyl;

R1 is H, C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

R2 and R3 each is, independently, H, -OH, -CN, -NO$_2$, F, Cl, Br, I, C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

8.  The chimeric analog of claim 1, wherein said chimeric analog comprises formula (VII),



(VII)

wherein:

P is –N(R3R4) or H;

L is –(CR5R6)$_m$-C(O)- or acyl;

Y is C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, substituted akylaryl, or absent;

R1, R2, R5 and R6 each is, independently, H, -OH, -CN, -NO$_2$, F, Cl, Br, I, C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

R3 and R4 each is, independently, H, C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.


9.    The chimeric analog of claim 1, wherein said chimeric analog comprises formula (VIII),



(VIII)

wherein:

X and Y each is, independently, -OH, -OR4 or R5-C(O)-O-;

L is –(CR3R4)$_m$-C(O)- or acyl;

R1, R2, R3 and R4 each is, independently, H, -OH, F, Cl, Br, I, -CN, NO$_2$, C$_{1-10}$ alkyl, substituted C$_{1-10}$ alkyl; C$_{1-10}$ heteroalkyl, substituted C$_{1-10}$ heteroalkyl, C$_{2-10}$ alkenyl, substituted C$_{2-10}$ alkenyl, C$_{2-10}$ alkynyl, substituted C$_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl; or R2 and R3 can, optionally, join together to form a ring system;

R5 is H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each occurrence, attached to an N-terminal or an internal amine group or hydroxyl group of Z.

10.  The chimeric analog of claim 1, wherein said chimeric analog comprises formula (IX),



(IX)

wherein:

X and Y each is, independently, -OH, -OR4 or R7-C(O)-;

Q is -(CR5R6)$_m$-C(O)- or acyl;

R1, R2, R3, R4, R5 and R6 each is, independently, H, -OH, F, Cl, Br, I, -CN, $NO_2$, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl; or R1 and R2 can, optionally, join together to form a ring system; or R3 and R4 can, optionally, join together to form a ring system;

R7 is H, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl, substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$ alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each

occurrence, attached to an N-terminal or an internal amine group or hydroxyl

group of Z.

11. The chimeric analog of claim 1, wherein said chimeric analog comprises formula

(X),



(X)

wherein:

Y is $-(CR8R9)_m-C(O)-$ or acyl;

R1, R2, R3, R4, R5, R6, R7, R8 and R9 each is, independently, H, -OH, F, Cl,

Br, I, -CN, $NO_2$, $C_{1-10}$ alkyl, substituted $C_{1-10}$ alkyl; $C_{1-10}$ heteroalkyl,

substituted $C_{1-10}$ heteroalkyl, $C_{2-10}$ alkenyl, substituted $C_{2-10}$ alkenyl, $C_{2-10}$

alkynyl, substituted $C_{2-10}$ alkynyl, aryl, alkylaryl, or substituted akylaryl;

i is 1-10;

m is 0-10;

Z is a ligand of at least one somatostatin receptor; or

a pharmaceutically acceptable salt thereof; and

wherein each moiety depicted between the brackets is, independently for each

occurrence, attached to an N-terminal or an internal amine group or hydroxyl

group of Z.

12. The chimeric analog of claim 1, wherein said chimeric analog comprises a compound

according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-$NH_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Ac)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop2-DLys(Ac)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop3-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop4-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop5-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop6-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop7-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop8-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop9-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop10-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop11-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop12-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop13-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop5-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop6-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂

Dop7-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop8-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop9-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop10-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop11-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop12-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop13-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop7-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop8-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop9-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop10-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop11-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop12-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop13-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop7-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop8-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop9-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop10-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop11-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop12-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop13-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop7-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop8-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop9-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop10-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop11-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop12-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop13-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop7-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop8-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop9-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop10-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop11-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop12-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop13-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop5-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop7-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop8-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop9-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop10-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop11-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop12-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop13-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop1-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop4-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop11-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop13-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop4-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop6-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop7-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop8-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop9-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop10-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop11-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop12-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop13-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop1-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop2-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop3-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop4-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop1-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop2-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop3-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop4-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop5-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop6-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop7-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop8-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop9-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop10-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop11-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop12-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop13-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop1-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop2-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop3-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop1-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop2-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop3-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop5-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop6-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop7-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop8-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop9-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop10-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop11-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop12-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop13-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-SerBzl)-Tyr-NH$_2$,

Dop5-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop6-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop7-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop8-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop9-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop10-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop11-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop12-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop13-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop5-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop11-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop13-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop11-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop13-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop1-Lys(Dop1)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop1-Lys(Dop1)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop1-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop1-Lys(Dop2)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop1-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop1-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop2-Lys(Dop2)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop2-Lys(Dop2)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-DLys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-DLys(Dop3)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-DLys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-DLys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-DLys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop3-Lys(Dop3)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop3-Lys(Dop3)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop3-Lys(Dop3)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop3-Lys(Dop3)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop3-Lys(Dop3)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DLys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DLys(Dop4)-Aepa-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DLys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DLys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DLys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop4-Lys(Dop4)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop4-Lys(Dop4)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop4-Lys(Dop4)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop4-Lys(Dop4)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop4-Lys(Dop4)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-Lys(Dop5)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop5-Lys(Dop5)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$ ,

Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-DLys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-DLys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-DLys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-Lys(Dop6)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop6-Lys(Dop6)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop6-Lys(Dop6)-Lys-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop6-Lys(Dop6)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop7-DLys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop7-DLys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop7-Lys(Dop7)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop7-Lys(Dop7)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop8-DLys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop8-DLys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop8-Lys(Dop8)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop8-Lys(Dop8)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop8-Lys(Dop8)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop9-DLys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop9-DLys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop9-Lys(Dop9)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop9-Lys(Dop9)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop9-Lys(Dop9)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop10-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop10-DLys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop10-Lys(Dop10)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop10-Lys(Dop10)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop10-Lys(Dop10)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop11-DLys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop11-DLys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop11-Lys(Dop11)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop11-Lys(Dop11)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop11-Lys(Dop11)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop12-DLys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop12-DLys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop12-Lys(Dop12)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop12-Lys(Dop12)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop12-Lys(Dop12)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop13-DLys(Dop10)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop13-DLys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-D2Nal-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop13-Lys(Dop13)-cyclo[Cys-Tyr-DTrp-Lys-Thr-Cys]-2Nal-NH$_2$,

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop13-Lys(Dop13)-cyclo[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-ol,

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop13-Lys(Dop13)- cyclo[Cys-Tyr-DTrp-Lys-Val-Cys]-Trp-NH$_2$,

Dop1-Lys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-DLys(Dop1)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop1-Lys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH$_2$,

Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-
Tyr-NH$_2$,

Dop1-DLys(Dop1)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH$_2$,

Dop2-Lys(Dop2)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-DLys(Dop2)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop2-DLys(Dop2)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop2-DLys(Dop2)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-
NH$_2$,

Dop2-DLys(Dop2)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-
NH$_2$,

Dop2-Lys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH$_2$,

Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-
Tyr-NH$_2$,

Dop2-DLys(Dop2)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH$_2$,

Dop3-Lys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop3-Lys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop3-Lys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH$_2$,

Dop3-Lys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH$_2$,

Dop3-DLys(Dop3)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop3-DLys(Dop3)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop3-DLys(Dop3)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-
NH₂,

Dop3-DLys(Dop3)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-Lys(Dop4)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop4-Lys(Dop4)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂

Dop4-Lys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂

Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂

Dop4-Lys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂

Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-
NH₂,

Dop4-Lys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH₂,

Dop4-DLys(Dop4)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop4-DLys(Dop4)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop4-DLys(Dop4)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-
NH₂,

Dop4-DLys(Dop4)-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-
Tyr-NH₂,

Dop4-DLys(Dop4)-Lys-Aepa-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-
NH₂,

Dop5-Lys(Dop5)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop5-Lys(Dop5)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop5-DLys(Dop5)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop5-DLys(Dop5)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop5-Lys(Dop5)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop5-DLys(Dop5)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop5-DLys(Dop5)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop6-Lys(Dop6)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop6-Lys(Dop6)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop6-DLys(Dop6)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop6-DLys(Dop6)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop6-Lys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop6-DLys(Dop6)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop7-Lys(Dop7)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop7-Lys(Dop7)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop7-Lys(Dop7)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop8-Lys(Dop8)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop8-Lys(Dop8)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop8-Lys(Dop8)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop9-Lys(Dop9)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop9-Lys(Dop9)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop9-Lys(Dop9)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop10-Lys(Dop10)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop10-Lys(Dop10)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop10-Lys(Dop10)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop11-Lys(Dop11)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop11-Lys(Dop11)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop11-Lys(Dop11)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop12-Lys(Dop12)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop12-Lys(Dop12)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop12-Lys(Dop12)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop13-Lys(Dop13)-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop13-Lys(Dop13)-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-3Pal-DTrp-Lys-DCys]-Thr(Bzl)-Tyr-NH₂,

Dop13-Lys(Dop13)-Lys-Caeg-cyclo[DCys-Phe-DTrp-Lys-DCys]-Ser(Bzl)-Tyr-NH₂,

Dop1-Lys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop1-DLys(Dop1)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop1-DLys(Dop1)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop1-Lys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop1-DLys(Dop1)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-DLys(Dop2)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-DLys(Dop2)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop3-Lys(Dop3)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop3-Lys(Dop3)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop4-Lys(Dop4)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop4-Lys(Dop4)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop5-Lys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop5-DLys(Dop5)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH₂,

Dop5-DLys(Dop5)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop5-Lys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop5-DLys(Dop5)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-DLys(Dop6)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop6-DLys(Dop6)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-DLys(Dop6)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-cyclo[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-NH$_2$,

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-Phe-(N-Me)DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-DPhe-cyclo[Cys-3ITyr(Dop1)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop1)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-Lys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop1-DLys(Dop1)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH<sub>2</sub>,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-Lys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-Aepa-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH<sub>2</sub>,

Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-Lys(Dop3)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop4-Lys(Dop4)-Aepa-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop5-DLys(Dop5)-Lys-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$, ·

Dop11-Lys(Dop11)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop13-Lys(Dop13)-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop6-Lys(Dop6)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop7-Lys(Dop7)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop8-Lys(Dop8)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop9-Lys(Dop9)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop10-Lys(Dop10)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop11-Lys(Dop11)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop12-Lys(Dop12)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$, or

Dop13-Lys(Dop13)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]- Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

13. The chimeric analog of claim 1, wherein said chimeric analog comprises a compound according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$ ,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$, or

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

14. The chimeric analog of claim 1, wherein said chimeric analog comprises a compound according to the formula of:

′ Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2, Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$, or

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

15. The chimeric analog of claim 14, wherein said chimeric analog comprises a compound according to the formula of:

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; or

a pharmaceutically acceptable salt thereof.

16. The chimeric analog of claim 14, wherein said chimeric analog comprises a
    compound according to the formula of:
    Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$; or
    a pharmaceutically acceptable salt thereof.

17. The chimeric analog of claim 14, wherein said chimeric analog comprises a
    compound zccording to the formula of:
    Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or
    a pharmaceutically acceptable salt thereof.

18. The chimeric analog of claim 1, wherein said chimeric analog comprises a compound
    according to the formula of:
    Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],
    Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or
    Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or
    a pharmaceutically acceptable salt thereof.

19. A compound useful as an intermediate in a chemical synthesis, wherein said
    intermediate comprises a compound according to the formula of:
    (3), (6), (11), (14), (18), (21), (24), or (27);

**6** ;



**11** ;



**14** ;



**18** ;



**21** ;

24

; or



27

or an organic or inorganic salt thereof.

20. A method of eliciting a dopamine receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a chimeric analogue of the invention, wherein said chimeric analogue comprises a compound according to the formula of

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or inorganic salt thereof; and

wherein said effective amount is the amount effective to elicit a dopamine receptor agonist effect in said subject.

21. The method of claim 20, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$, or

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

22. The method of claim 21, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2, Dop2-
DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$, or
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or
a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; or
a pharmaceutically acceptable salt thereof.

24. The method of claim 22, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$; or
a pharmaceutically acceptable salt thereof.

25. The method of claim 22, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or
a pharmaceutically acceptable salt thereof.

26. The method of claim 20, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or a pharmaceutically acceptable salt thereof.

27. A method of eliciting a somatostatin receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a chimeric analogue of the invention, wherein said chimeric analogue comprises a compound according to the formula of:

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or inorganic salt thereof; and

wherein said effective amount is the amount effective to elicit a dopamine receptor agonist effect in said subject.

28. The method of claim 27, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

124

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, or

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or

a pharmaceutically acceptable salt thereof.


29. The method of claim 28, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2, Dop2-
DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or
a pharmaceutically acceptable salt thereof.


30. The method of claim 29, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2;
a pharmaceutically acceptable salt thereof.


31. The method of claim 29, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or
a pharmaceutically acceptable salt thereof.


32. The method of claim 29, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or
a pharmaceutically acceptable salt thereof.


33. The method of claim 27, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

34. A method of eliciting both a dopamine receptor agonist effect and a somatostatin receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a chimeric analogue of the invention, wherein said chimeric analogue comprises a compound according to the formula of

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or inorganic salt thereof; and

wherein said effective amount is the amount effective to elicit both a dopamine receptor agonist effect and a somatostatin receptor agonist effect in said subject.

35. The method of claim 34, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$ ,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂, or

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂; or

a pharmaceutically acceptable salt thereof.

36. The method of claim 35, wherein said chimeric analogue comprises a compound
according to the formula of
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2, Dop2-
DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2; or
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH2.or
a pharmaceutically acceptable salt thereof.

37. The method of claim 36, wherein said chimeric analogue comprises a compound
according to the formula of
Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2;
a pharmaceutically acceptable salt thereof.

38. The method of claim 36, wherein said chimeric analogue comprises a compound
according to the formula of
Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂; or
a pharmaceutically acceptable salt thereof.

39. The method of claim 36, wherein said chimeric analogue comprises a compound
according to the formula of
Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂.or
a pharmaceutically acceptable salt thereof.

40. The method of claim 34, wherein said chimeric analogue comprises a compound
according to the formula of:
Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],
Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or
Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; or
a pharmaceutically acceptable salt thereof.

41. A pharmaceutical composition comprising an effective amount of a compound according to the formula of:

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or inorganic salt thereof;

in a pharmaceutically acceptable carrier, wherein said effective amount is the amount effective to elicit a dopamine receptor agonist effect or a somatostatin receptor agonist effect or both in a subject in need thereof.

42. The pharmaceutical composition of claim 41, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$, or

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

43. The pharmaceutical composition of claim 42, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2, Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$; or

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$.or

a pharmaceutically acceptable salt thereof.

44. The pharmaceutical composition of claim 43, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2;

a pharmaceutically acceptable salt thereof.

45. The pharmaceutical composition of claim 43, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

46. The pharmaceutical composition of claim 43, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$.or

a pharmaceutically acceptable salt thereof.

47. The pharmaceutical composition of claim 41, wherein said chimeric analogue comprises a compound according to the formula of:

Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or

a pharmaceutically acceptable salt thereof.

48. A method of treating a disease or condition in a subject, said method comprising administering to said subject a therapeutically effective amount of a chimeric analog, wherein said chimeric analog comprises a compound according to the formula of:

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or

a pharmaceutically acceptable salt thereof; or

intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or inorganic salt thereof; and

wherein said disease or disorder is selected from the list consisting of

a neuroendocrine tumor;

a vascular disease;

a connective tissue disease;

an immune disease;

a disorder of the gastrointestinal tract, pancreas, kidney, or liver;

a metabolic disease;

130

a cachexia;

cancer or a tumor of the lung, breast, prostate, liver, thyroid, blood;

a musculoskeletal disorder;

a panic disorder; and

opioid overdose; and

wherein said therapeutically effective amount is the amount effective to treat said

disease or disorder in said patient.

49. The method of claim 48, wherein said neuroendocrine tumor is a neuroendocrine
tumor of the pituitary.

50. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is an
ACTH-producing tumor.

51. The method of claim 50, wherein the condition of said ACTH-producing tumor is
Cushing's disease.

52. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is a
growth hormone producing tumor.

53. The method of claim 52, wherein the condition of said growth hormone producing
tumor is acromegaly.

54. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is a
prolactin-producing tumor.

55. The method of claim 54, wherein the condition of said prolactin-producing tumor is a
prolactinoma.

56. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is
hyperprolactinemia.

57. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is thyroid stimulating hormone (TSH) secreting tumor.

58. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is "nonfunctioning" pituitary adenoma.

59. The method of claim 49, wherein said neuroendocrine tumor of the pituitary is gonadotropinoma.

60. The method of claim 48, wherein the neuroendocrine tumor is carcinoid tumor.

61. The method of claim 60, wherein said carcinoid tumor causes carcinoid syndrome.

62. The method of claim 48, wherein said neuroendocrine tumor is glucagonoma.

63. The method of claim 48, wherein said neuroendocrine tumor is small cell lung carcinoma.

64. The method of claim 48, wherein said neuroendocrine tumor is thyroid medullary carcinoma.

65. The method of claim 48, wherein said neuroendocrine tumor is VIPoma.

66. The method of claim 48, wherein said neuroendocrine tumor is insulinoma.

67. The method of claim 48, wherein the disorder of said vascular disease is inappropriate angiogenesis.

68. The method of claim 48, wherein the disorder of said vascular disease is restenosis.

69. The method of claim 48, wherein the disorder of said vascular disease is retinopathy.

70. The method of claim 69, wherein said retinopathy is diabetic retinopathy.

71. The method of claim 69, wherein said retinopathy is proliferative retinopathy.

72. The method of claim 69, wherein said retinopathy is macular degeneration.

73. The method of claim 72, wherein said macular degeneration is age-related macular degeneration.

74. The method of claim 48, wherein said connective tissue disease is scleroderma.

75. The method of claim 48, wherein said immune disease is rheumatoid arthritis.

76. The method of claim 48, wherein said immune disease is inflammation.

77. The method of claim 48, wherein said immune disease is fibrosis.

78. The method of claim 48, wherein said immune disease is Graves' opthalmopathy.

79. The method of claim 48, wherein said immune disease is allograft rejection.

80. The method of claim 48, wherein said disorder of the gastrointestinal tract comprises gastric acid secretion, peptic ulcers, inflammatory bowel disease (IBD), or diarrhea.

81. The method of claim 80, wherein said IBD is irritable bowel syndrome or Crohn's disease.

82. The method of claim 48, wherein said metabolic disease comprises hyperlipidemia, insulin resistance, Syndrome X, obesity, diabetes, or a diabetes-related disease.

83. The method of claim 82, wherein said diabetes-related disease comprises diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, or gastroparesis.

84. The method of claim 48, wherein said cachexia is cardiac cachexia, cancer cachexia, or geriatric cachexia.

85. The method of any of claims 58 to 84, wherein said chimeric analog comprises a SSTR-1 agonist and a dopamine receptor agonist; or a pharmaceutically acceptable salt thereof.

86. The method of claim 85, wherein said chimeric analog further comprises a SSTR-2 agonist.

87. The method of claim 85, wherein said chimeric analog further comprises a SSTR-3 agonist.

88. The method of claim 86, wherein said chimeric analog further comprises a SSTR-3 agonist.

89. The method of claim 85, wherein said chimeric analog further comprises a SSTR-5 agonist.

90. The method of claim 86, wherein said chimeric analog further comprises a SSTR-5 agonist.

91. The method of claim 87, wherein said chimeric analog further comprises a SSTR-5 agonist.

92. The method of claim 88, wherein said chimeric analog further comprises a SSTR-5 agonist.

93. The method of any of claims 48 to 84, wherein said chimeric analog comprises a SSTR-2 agonist and a dopamine receptor agonist; or a pharmaceutically acceptable salt thereof.

94. The method of claim 93, wherein said chimeric analog further comprises a SSTR-5 agonist.

95. The method of any of claims 48 to 84, wherein said chimeric analog comprises a SSTR-3 agonist and a dopamine receptor agonist; or a pharmaceutically acceptable salt thereof.

96. The method of any of claims 48 to 84, wherein said chimeric analog comprises a SSTR-5 agonist and a dopamine receptor agonist; or a pharmaceutically acceptable salt thereof.

97. A method of treating acromegaly in a subject in need thereof, wherein said method comprises administering to said subject a therapeutically effective amount of a chimeric analog, wherein said chimeric analog comprises a compound according to the formula of:

Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically acceptable salt thereof;

a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH₂; or

a pharmaceutically acceptable salt thereof; or

intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or

inorganic salt thereof; and

wherein said therapeutically effective amount is the amount effective to treat

acromegaly in said patient.

98. The method of claim 97, wherein said chimeric analog comprises a SSTR-5 agonist
    and a dopamine receptor agonist.

99. The method of claim 98, wherein said chimeric analog further comprises a SSTR-2
    agonist.

100. A method of treating prolactinemia in a subject in need thereof, wherein said method
    comprises administering to said subject a therapeutically effective amount of a
    chimeric analog, wherein said chimeric analog comprises a compound according to
    the formula of:

    Formula (I), (II), (III), (IV), (V), (VI) (VII), (VIII), (IX), or (X); or a pharmaceutically
    acceptable salt thereof;

    a compound according to claim 12; or a pharmaceutically acceptable salt thereof; or

    Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Val-Cys]-Thr-NH₂,

    Dop2-DPhe-Doc-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH₂,

    Ac-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

    Ac-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂,

    Dop3-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

    Dop4-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

    Dop5-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

    Dop2-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH₂ ,

    Dop2-Lys(Dop2)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH₂,

Dop2-Lys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop5-Lys(Dop5)-DPhe-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH$_2$,

Dop2-DPhe-cyclo[Cys-3ITyr(Dop2)-DTrp-Lys-Val-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-DTyr-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-DLys(Dop2)-DPhe-cyclo[Cys-3ITyr-DTrp-Lys-Thr-Cys]-Thr-NH$_2$,

Dop2-Lys(Dop2)-DTyr-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe],

Dop2-Tyr-cyclo[DDab-Arg-Phe-Phe-DTrp-Lys-Thr-Phe], or

Dop2-DTyr-DTyr-Caeg-cyclo[DCys-3Pal-DTrp-Lys-Dcys]-Thr(Bzl)-Tyr-NH$_2$; or

a pharmaceutically acceptable salt thereof; or

intermediate compound (3), (6), (11), (14), (18), (21), (24), or (27); or an organic or

inorganic salt thereof; and

wherein said therapeutically effective amount is the amount effective to treat

prolactinemia in said patient.

101. The method of claim 100, wherein said chimeric analog comprises a SSTR-5 agonist
and a dopamine receptor agonist.

102. The method of claim 101, wherein said chimeric analog further comprises a SSTR-2
agonist.